File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma

TitleReal world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma
Authors
KeywordsGemcitabine
maintenance chemotherapy
chemotherapy
second line chemotherapy
lung cancer
Issue Date2020
PublisherTaylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/yjoc20
Citation
Journal of Chemotherapy, 2020, v. 32 n. 8, p. 429-436 How to Cite?
AbstractMaintenance chemotherapy was studied in first line setting for advanced stage non-small cell lung carcinoma (NSCLC). There has not been any data on the role of continuation maintenance chemotherapy in second line setting. A retrospective cohort study that included 226 patients with advanced stage NSCLC that received second line gemcitabine ± platinum was conducted. Patients who had continuation maintenance gemcitabine were compared with those who went on drug holiday. The primary endpoint was progression-free survival (PFS), counted from the end of induction therapy. The median PFS was significantly longer for patients who continued with maintenance gemcitabine when compared with those on drug holiday (5.6 vs 1.7 months, HR 0.392, p-value < 0.001). The overall survival was also significantly longer (21.4 vs 15.8 months, HR 0.508, p-value 0.047). There was no increase in incidence of adverse events for patients who underwent maintenance gemcitabine. Continuation maintenance therapy with gemcitabine in second line setting is a potentially feasible and safe option for patients with advanced NSCLC.
Persistent Identifierhttp://hdl.handle.net/10722/293399
ISSN
2020 Impact Factor: 1.714
2020 SCImago Journal Rankings: 0.515
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorKwok, WC-
dc.contributor.authorLam, DCL-
dc.contributor.authorChiang, KY-
dc.contributor.authorHo, JCM-
dc.contributor.authorIp, MSM-
dc.contributor.authorTam, TCC-
dc.date.accessioned2020-11-23T08:16:11Z-
dc.date.available2020-11-23T08:16:11Z-
dc.date.issued2020-
dc.identifier.citationJournal of Chemotherapy, 2020, v. 32 n. 8, p. 429-436-
dc.identifier.issn1120-009X-
dc.identifier.urihttp://hdl.handle.net/10722/293399-
dc.description.abstractMaintenance chemotherapy was studied in first line setting for advanced stage non-small cell lung carcinoma (NSCLC). There has not been any data on the role of continuation maintenance chemotherapy in second line setting. A retrospective cohort study that included 226 patients with advanced stage NSCLC that received second line gemcitabine ± platinum was conducted. Patients who had continuation maintenance gemcitabine were compared with those who went on drug holiday. The primary endpoint was progression-free survival (PFS), counted from the end of induction therapy. The median PFS was significantly longer for patients who continued with maintenance gemcitabine when compared with those on drug holiday (5.6 vs 1.7 months, HR 0.392, p-value < 0.001). The overall survival was also significantly longer (21.4 vs 15.8 months, HR 0.508, p-value 0.047). There was no increase in incidence of adverse events for patients who underwent maintenance gemcitabine. Continuation maintenance therapy with gemcitabine in second line setting is a potentially feasible and safe option for patients with advanced NSCLC.-
dc.languageeng-
dc.publisherTaylor & Francis. The Journal's web site is located at http://www.tandfonline.com/loi/yjoc20-
dc.relation.ispartofJournal of Chemotherapy-
dc.rightsThis is an Accepted Manuscript of an article published by Taylor & Francis in [JOURNAL TITLE] on [date of publication], available online: http://www.tandfonline.com/[Article DOI].-
dc.subjectGemcitabine-
dc.subjectmaintenance chemotherapy-
dc.subjectchemotherapy-
dc.subjectsecond line chemotherapy-
dc.subjectlung cancer-
dc.titleReal world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma-
dc.typeArticle-
dc.identifier.emailLam, DCL: dcllam@hku.hk-
dc.identifier.emailHo, JCM: jhocm@hku.hk-
dc.identifier.emailIp, MSM: msmip@hku.hk-
dc.identifier.authorityLam, DCL=rp01345-
dc.identifier.authorityHo, JCM=rp00258-
dc.identifier.authorityIp, MSM=rp00347-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/1120009X.2020.1829325-
dc.identifier.pmid33043860-
dc.identifier.hkuros320116-
dc.identifier.volume32-
dc.identifier.issue8-
dc.identifier.spage429-
dc.identifier.epage436-
dc.identifier.isiWOS:000579135700001-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats